Study Objectives and Hypothesis To determine the incidence of hyponatremia at TYKS and the factors associated with it. To assess how rapidly hyponatremia was corrected and how the rate of correction affected patient prognosis. To evaluate treatment modalities and their impact on patient prognosis, length of hospital stay, and their appropriateness in comparison with national and international treatment guidelines. To determine the incidence of osmotic demyelination at TYKS and the factors associated with it. To assess other complications and their clinical significance. To evaluate the impact of hyponatremia on various endpoints, such as mortality, length of hospital stay, seizures, confusion, and similar outcomes.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Prevalence of ODS in hyponatremia patients
Timeframe: From enrollment to the end of the treamtent period. Usually 2-21 days.
Osmotic demyelination syndrome
Timeframe: During the study period 1.1.2010-31.12.2020 wiht recorded sodium values.